Aortic Valve Replacement in Young and Middle-Aged Adults: Current and Potential Roles of TAVR

Nelson, Jennifer S.; Maul, Timothy M.; Wearden, Peter D.; Najm, Hani K.; Baloğlu, Orkun; Johnston, Douglas R.; Karamlou, Tara

doi:10.1016/j.athoracsur.2020.05.180

Cited by 14 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The long-term durability outcomes of the first-generation valves presented at the 2016 EuroPCR conference suggested that TAVR devices may be comparable to SAVR devices if the same definition of structural valve degeneration is used, with a time from operation to valve deterioration and re-intervention ranging between 7 and 11 years postoperatively [48] . However, some studies have indicated that young patients who received TAVR might have a worse prognosis than old patients [49,50] . The NOTION II RCT planned to include surgically low-risk patients aged <75 years and compare the long-term follow-up outcomes for 5 to 10 years between patients who underwent TAVR and those who underwent SAVR, which is expected to provide more data on TAVR use in young patients.…”

Section: Transcatheter Aortic Valve Replacement (Tavr)mentioning

confidence: 99%

“…[48] However, some studies have indicated that young patients who received TAVR might have a worse prognosis than old patients. [49,50] The NOTION II RCT planned to include surgically low-risk patients aged <75 years and compare the long-term follow-up outcomes for 5 to 10 years between patients who underwent TAVR and those who underwent SAVR, which is expected to provide more data on TAVR use in young patients.…”

Section: Young Patients Requiring Tavrmentioning

confidence: 99%

See 1 more Smart Citation

Current Status and Challenges of Valvular Heart Disease Interventional Therapy

Zhang

Xiong

Feng

2022

Cardiology Discovery

View full text Add to dashboard Cite

Valvular heart disease (VHD) is common in the global population, occupying an heavy disease burden among aging population. Currently, it is the booming era of transcatheter VHD treatment, even with superiority than traditional open heart surgery in some clinical outcomes. We collected data sources mainly derived from published articles and conference presentations, including randomized controlled trials, first-in-man studies, clinical registries, and other single-or multi-center and prospective or retrospective clinical studies. This review summarized the relevant devices and researches of transcatheter aortic valve replacement, transcatheter mitral valve repair and replacement, transcatheter tricuspid valve repair and replacement, and transcatheter pulmonary valve replacement. Moreover, possible challenges of interventional therapy for various VHD in the future were discussed as well.

show abstract

Section: Transcatheter Aortic Valve Replacement (Tavr)mentioning

confidence: 99%

Section: Young Patients Requiring Tavrmentioning

confidence: 99%

Current Status and Challenges of Valvular Heart Disease Interventional Therapy

Zhang

Xiong

Feng

2022

Cardiology Discovery

View full text Add to dashboard Cite

show abstract

“…These data will be important to guide management of younger patients with aortic stenosis, as these patients may still benefit from SAVR instead of TAVR due to a longer expected life span. 8,9 Unfortunately, the increasing prevalence of comorbid conditions like end stage renal disease or cancer among valvular surgery patients may impede subclassification of valve-related mortality, particularly in cases of out of hospital death or where autopsy is not performed. 10 This may weaken the ability of observational registry studies comparing TAVR and SAVR to distinguish differences in valve-related mortality, and emphasizes the important of rigorous surveillance of existing clinical trial participants.…”

Section: Changes In Clinical Endpointsmentioning

confidence: 99%

Focusing on the Long Game: Updates on Aortic Valve Research From the Valve Academic Research Consortium

Weimer

Vanneman

2021

Journal of Cardiothoracic and Vascular Anesthesia

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…TAVR use is increasing rapidly among young adult patients in recent years (40). Although TAVR may be an appealing option for young adults with severe AS in general due to faster recovery, avoidance of a chest scar, no need for general anesthesia, in certain subgroups of young but frail patients TAVR might de facto be the only feasible option due to their high surgical risk (38).…”

Section: Young Patients At High Surgical Riskmentioning

confidence: 99%

Transcatheter Aortic Valve Replacement in Young Low-Risk Patients With Severe Aortic Stenosis: A Review

Bocchino

Angelini

Alushi

et al. 2020

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

In the last decades, transcatheter aortic valve replacement (TAVR) revolutionized the treatment of symptomatic severe aortic stenosis. The efficacy and safety of TAVR were first proven in inoperable and high-risk patients. Then, subsequent randomized clinical trials showed non-inferiority of TAVR as compared to surgical aortic valve replacement also in intermediate- and low-risk populations. As TAVR was progressively studied and clinically used in lower-risk patients, issues were raised questioning its opportunity in a younger population with a longer life-expectancy. As long-term follow-up data mainly derive from old studies with early generation devices on high or intermediate surgical risk patients, results can hardly be extended to most of currently treated patients who often show a low surgical risk and are treated with newer generation prostheses. Thus, in this low-risk younger population, decision making is difficult due to the lack of supporting data. The aim of the present review is to revise current literature regarding TAVR in younger patients.

show abstract

Aortic Valve Replacement in Young and Middle-Aged Adults: Current and Potential Roles of TAVR

Cited by 14 publications

References 13 publications

Current Status and Challenges of Valvular Heart Disease Interventional Therapy

Current Status and Challenges of Valvular Heart Disease Interventional Therapy

Focusing on the Long Game: Updates on Aortic Valve Research From the Valve Academic Research Consortium

Transcatheter Aortic Valve Replacement in Young Low-Risk Patients With Severe Aortic Stenosis: A Review

Contact Info

Product

Resources

About